Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data
CONCLUSIONS: The increase in H3K9ac appears to enhance the recruitment of the transcription factor SP1 to its binding sites within the MGMT locus, consequently upregulating MGMT expression and driving TMZ resistance in GBM.PMID:38448295 | DOI:10.1111/cns.14649 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - March 6, 2024 Category: Neuroscience Authors: Liguo Ye Lingui Gu Yaning Wang Hao Xing Pengtao Li Xiaopeng Guo Yu Wang Wenbin Ma Source Type: research
CD133 significance in glioblastoma development: in silico and in vitro study
CONCLUSION: CD133 can regulate the PI3K/Akt and MAPK pathways and modulate the clonogenicity, apoptosis, and cell cycle of GBM. Combining CD133 silencing with temozolomide treatment considerably increases apoptosis, arrests the cell cycle at the sub-G1, and suppresses migration of U87MG cells compared to temozolomide monotherapy.PMID:38448914 | DOI:10.1186/s40001-024-01754-2 (Source: Cell Research)
Source: Cell Research - March 6, 2024 Category: Cytology Authors: Mahdi Abdoli Shadbad Fatemeh Nejadi Orang Behzad Baradaran Source Type: research
RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3- β pathway
Cancer Biol Ther. 2024 Dec 31;25(1):2321770. doi: 10.1080/15384047.2024.2321770. Epub 2024 Mar 5.ABSTRACTGBM is one of the most malignant tumor in central nervous system. The resistance to temozolomide (TMZ) is inevitable in GBM and the characterization of TMZ resistance seriously hinders clinical treatment. It is worthwhile exploring the underlying mechanism of aggressive invasion and TMZ resistance in GBM treatment. Bioinformatic analysis was used to analyze the association between RND1 and a series of EMT-related genes. Colony formation assay and cell viability assay were used to assess the growth of U87 and U251 cells....
Source: Cancer Biology and Therapy - March 6, 2024 Category: Cancer & Oncology Authors: Qian Sun Junjie Xu Fan'en Yuan Yan Liu Qianxue Chen Lirui Guo Huimin Dong Baohui Liu Source Type: research
Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data
CONCLUSIONS: The increase in H3K9ac appears to enhance the recruitment of the transcription factor SP1 to its binding sites within the MGMT locus, consequently upregulating MGMT expression and driving TMZ resistance in GBM.PMID:38448295 | PMC:PMC10917648 | DOI:10.1111/cns.14649 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - March 6, 2024 Category: Neuroscience Authors: Liguo Ye Lingui Gu Yaning Wang Hao Xing Pengtao Li Xiaopeng Guo Yu Wang Wenbin Ma Source Type: research
RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3- β pathway
Cancer Biol Ther. 2024 Dec 31;25(1):2321770. doi: 10.1080/15384047.2024.2321770. Epub 2024 Mar 5.ABSTRACTGBM is one of the most malignant tumor in central nervous system. The resistance to temozolomide (TMZ) is inevitable in GBM and the characterization of TMZ resistance seriously hinders clinical treatment. It is worthwhile exploring the underlying mechanism of aggressive invasion and TMZ resistance in GBM treatment. Bioinformatic analysis was used to analyze the association between RND1 and a series of EMT-related genes. Colony formation assay and cell viability assay were used to assess the growth of U87 and U251 cells....
Source: Cancer Biology and Therapy - March 6, 2024 Category: Cancer & Oncology Authors: Qian Sun Junjie Xu Fan'en Yuan Yan Liu Qianxue Chen Lirui Guo Huimin Dong Baohui Liu Source Type: research
Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data
CONCLUSIONS: The increase in H3K9ac appears to enhance the recruitment of the transcription factor SP1 to its binding sites within the MGMT locus, consequently upregulating MGMT expression and driving TMZ resistance in GBM.PMID:38448295 | PMC:PMC10917648 | DOI:10.1111/cns.14649 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - March 6, 2024 Category: Neuroscience Authors: Liguo Ye Lingui Gu Yaning Wang Hao Xing Pengtao Li Xiaopeng Guo Yu Wang Wenbin Ma Source Type: research
RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3- β pathway
Cancer Biol Ther. 2024 Dec 31;25(1):2321770. doi: 10.1080/15384047.2024.2321770. Epub 2024 Mar 5.ABSTRACTGBM is one of the most malignant tumor in central nervous system. The resistance to temozolomide (TMZ) is inevitable in GBM and the characterization of TMZ resistance seriously hinders clinical treatment. It is worthwhile exploring the underlying mechanism of aggressive invasion and TMZ resistance in GBM treatment. Bioinformatic analysis was used to analyze the association between RND1 and a series of EMT-related genes. Colony formation assay and cell viability assay were used to assess the growth of U87 and U251 cells....
Source: Cancer Biology and Therapy - March 6, 2024 Category: Cancer & Oncology Authors: Qian Sun Junjie Xu Fan'en Yuan Yan Liu Qianxue Chen Lirui Guo Huimin Dong Baohui Liu Source Type: research
RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3- β pathway
Cancer Biol Ther. 2024 Dec 31;25(1):2321770. doi: 10.1080/15384047.2024.2321770. Epub 2024 Mar 5.ABSTRACTGBM is one of the most malignant tumor in central nervous system. The resistance to temozolomide (TMZ) is inevitable in GBM and the characterization of TMZ resistance seriously hinders clinical treatment. It is worthwhile exploring the underlying mechanism of aggressive invasion and TMZ resistance in GBM treatment. Bioinformatic analysis was used to analyze the association between RND1 and a series of EMT-related genes. Colony formation assay and cell viability assay were used to assess the growth of U87 and U251 cells....
Source: Cancer Biology and Therapy - March 6, 2024 Category: Cancer & Oncology Authors: Qian Sun Junjie Xu Fan'en Yuan Yan Liu Qianxue Chen Lirui Guo Huimin Dong Baohui Liu Source Type: research
CD133 significance in glioblastoma development: in silico and in vitro study
ConclusionCD133 can regulate the PI3K/Akt and MAPK pathways and modulate the clonogenicity, apoptosis, and cell cycle of GBM. CombiningCD133 silencing with temozolomide treatment considerably increases apoptosis, arrests the cell cycle at the sub-G1, and suppresses migration of U87MG cells compared to temozolomide monotherapy.Graphical Abstract (Source: European Journal of Medical Research)
Source: European Journal of Medical Research - March 6, 2024 Category: Research Source Type: research
Glioma-targeted oxaliplatin/ferritin clathrate reversing the immunosuppressive microenvironment through hijacking Fe2+ and boosting Fenton reaction
Glioma is easy to develop resistance to temozolomide (TMZ). TMZ-resistant glioma secretes interleukin-10 (IL-10) and transforming growth factor- β (TGF-β), recruiting regulatory T cell (Treg) and inhibiting the ac... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - March 5, 2024 Category: Nanotechnology Authors: Xue Li, Ying Cheng, Zhifu Yang, Qifeng Ji, Menglei Huan, Weiliang Ye, Miao Liu, Bangle Zhang, Daozhou Liu and Siyuan Zhou Tags: Research Source Type: research
Relapsed isolated CNS lymphoma treated with radiotherapy and intrathecal methotrexate followed by high ‐dose intravenous methotrexate, rituximab, and temozolomide: A case report
Key Clinical MessageOptimized treatments for relapsed isolated CNS lymphoma (RI-SCNSL) remains under investigation. Temozolomide combination-based therapy, which is often used in glioblastoma may be used as potential treatment in RI-SCNSL.AbstractOne of the most common types of non-Hodgkin lymphoma (NHL) is diffuse large B-cell lymphoma (DLBCL). Despite advances in treatment, relapsed isolated CNS lymphoma (RI-SCNSL) from DLBCL remains an issue. The optimal approach in RI-SCNSL remains an area of active investigation as currently there is no high level of evidence for the treatments due to lack of randomized studies. In th...
Source: Clinical Case Reports - March 2, 2024 Category: General Medicine Authors: Ikhwan Rinaldi,
Abdul Muthalib,
Soehartati Gondhowiardjo,
Tjondro Setiawan,
Andhika Gunawan,
Nelly Susanto,
Lingga Magdalena,
Kevin Winston,
Ashila Disamantiji,
Bintang Wirawan Tags: CASE REPORT Source Type: research
AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy
In this study, we synthesized AGCM-22, an EGFR-targeted ADC derived from cetuximab, by conjugating it with the tubulin inhibitor monomethyl auristatin E (MMAE) using our Valine-Alanine Cathepsin B cleavable linker. In vitro experiments demonstrated that AGCM-22 effectively inhibited GBM cell proliferation through increased levels of apoptosis and autophagy-related cell death, whereas cetuximab alone had no anti-GBM effects. Additionally, both mouse and human orthotopic tumor models exhibited the selective tumor-targeting efficacy of AGCM-22, along with favorable metabolic properties and superior anti-GBM activity compared ...
Source: Bioorganic and Medicinal Chemistry - March 1, 2024 Category: Chemistry Authors: Dapeng Li Xianyan Sun Yiquan Li Chao Shang Yuchao Dong Renshuang Zhao Hang Zhang Zihao Wang Shiyong Fan Chengyuan Ma Xiao Li Source Type: research
AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy
In this study, we synthesized AGCM-22, an EGFR-targeted ADC derived from cetuximab, by conjugating it with the tubulin inhibitor monomethyl auristatin E (MMAE) using our Valine-Alanine Cathepsin B cleavable linker. In vitro experiments demonstrated that AGCM-22 effectively inhibited GBM cell proliferation through increased levels of apoptosis and autophagy-related cell death, whereas cetuximab alone had no anti-GBM effects. Additionally, both mouse and human orthotopic tumor models exhibited the selective tumor-targeting efficacy of AGCM-22, along with favorable metabolic properties and superior anti-GBM activity compared ...
Source: Bioorganic and Medicinal Chemistry - March 1, 2024 Category: Chemistry Authors: Dapeng Li Xianyan Sun Yiquan Li Chao Shang Yuchao Dong Renshuang Zhao Hang Zhang Zihao Wang Shiyong Fan Chengyuan Ma Xiao Li Source Type: research
AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy
In this study, we synthesized AGCM-22, an EGFR-targeted ADC derived from cetuximab, by conjugating it with the tubulin inhibitor monomethyl auristatin E (MMAE) using our Valine-Alanine Cathepsin B cleavable linker. In vitro experiments demonstrated that AGCM-22 effectively inhibited GBM cell proliferation through increased levels of apoptosis and autophagy-related cell death, whereas cetuximab alone had no anti-GBM effects. Additionally, both mouse and human orthotopic tumor models exhibited the selective tumor-targeting efficacy of AGCM-22, along with favorable metabolic properties and superior anti-GBM activity compared ...
Source: Bioorganic and Medicinal Chemistry - March 1, 2024 Category: Chemistry Authors: Dapeng Li Xianyan Sun Yiquan Li Chao Shang Yuchao Dong Renshuang Zhao Hang Zhang Zihao Wang Shiyong Fan Chengyuan Ma Xiao Li Source Type: research
AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy
In this study, we synthesized AGCM-22, an EGFR-targeted ADC derived from cetuximab, by conjugating it with the tubulin inhibitor monomethyl auristatin E (MMAE) using our Valine-Alanine Cathepsin B cleavable linker. In vitro experiments demonstrated that AGCM-22 effectively inhibited GBM cell proliferation through increased levels of apoptosis and autophagy-related cell death, whereas cetuximab alone had no anti-GBM effects. Additionally, both mouse and human orthotopic tumor models exhibited the selective tumor-targeting efficacy of AGCM-22, along with favorable metabolic properties and superior anti-GBM activity compared ...
Source: Bioorganic and Medicinal Chemistry - March 1, 2024 Category: Chemistry Authors: Dapeng Li Xianyan Sun Yiquan Li Chao Shang Yuchao Dong Renshuang Zhao Hang Zhang Zihao Wang Shiyong Fan Chengyuan Ma Xiao Li Source Type: research
